Co-Infection Talaromyces marneffei and Pneumocystis jirovecii in a Patient with Systemic Lupus Erythematosus

References

• Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update omicron the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14–25. doi:10.1136/annrheumdis-2020-218272
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 2017;32(3):429–438. doi:10.3904/kjim.2016.234
   PubMed Web of Science ®Google Scholar
• Fei Y, Shi X, Gan F, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. Clin Rheumatol. 2014;33(1):57–63. doi:10.1007/s10067-013-2383-3
   PubMed Web of Science ®Google Scholar
• Wei J, Qiu Y, Zeng W, Pan M, Zhang J. Talaromyces marneffei infection in systemic lupus erythematosus patients: report of two cases and review of the literature. Infect Drug Resist. 2020;13:3811–3816. doi:10.2147/IDR.S265479
   PubMed Web of Science ®Google Scholar
• Chong YB, Tan LP, Robinson S, et al. Penicilliosis in lupus patients presenting with unresolved fever: a report of 2 cases and literature review. Trop Biomed. 2012;29(2):270–276.
   PubMed Web of Science ®Google Scholar
• Wang WH, Lai CC, Huang YF, et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Arthritis Care Res. 2022;74(9):1444–1450. doi:10.1002/acr.24584
   Web of Science ®Google Scholar
• Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol. 2020;16(5):527–538. doi:10.1080/1744666X.2020.1763793
   PubMed Web of Science ®Google Scholar
• Wolfe RM, Peacock JE Jr. Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep. 2017;19(6):35. doi:10.1007/s11926-017-0664-6
   PubMed Web of Science ®Google Scholar
• Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol. 2005;15(2):91–96. doi:10.1007/pl00021707
   PubMedGoogle Scholar
• Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis. 1997;175(4):901–904. doi:10.1086/513988
   PubMed Web of Science ®Google Scholar
• Yeo KJ, Chen HH, Chen YM, et al. Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. BMC Infect Dis. 2020;20(1):112. doi:10.1186/s12879-020-4826-1
   PubMed Web of Science ®Google Scholar
• Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–2498. doi:10.1056/NEJMra032588
   PubMed Web of Science ®Google Scholar
• Schmidt JJ, Lueck C, Ziesing S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care. 2018;22(1):307. doi:10.1186/s13054-018-2221-8
   PubMedGoogle Scholar
• Dennis GJ. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther. 2012;91(1):143–149. doi:10.1038/clpt.2011.290
   PubMed Web of Science ®Google Scholar
• Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi:10.1002/14651858.CD010668.pub2
   PubMedGoogle Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128. doi:10.1056/NEJMoa2001180
   PubMed Web of Science ®Google Scholar
• Levy RA, Gonzalez-Rivera T, Khamashta M, et al. 10 Years of belimumab experience: what have we learnt? Lupus. 2021;30(11):1705–1721. doi:10.1177/09612033211028653
   PubMed Web of Science ®Google Scholar
• Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(10):3364–3373. doi:10.1002/art.34564
   PubMed Web of Science ®Google Scholar
• Fredericks CA, Kvam KA, Bear J, Crabtree GS, Josephson SA. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus. 2014;23(7):711–713. doi:10.1177/0961203314524292
   PubMed Web of Science ®Google Scholar
• Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf. 2016;15(8):1003–1011. doi:10.1080/14740338.2016.1198775
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a Phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109. doi:10.1186/ar2506
   PubMed Web of Science ®Google Scholar
• Ng WL, Chu CM, Wu AK, Cheng VC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM. 2006;99(1):37–47. doi:10.1093/qjmed/hci155
   PubMed Web of Science ®Google Scholar
• Luu VP, Vazquez MI, Zlotnik A. B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity. 2014;47(1):1–12. doi:10.3109/08916934.2013.856006
   PubMed Web of Science ®Google Scholar
• Sone K, Muramatsu H, Nakao M, et al. Pneumocystis pneumonia secondary to idiopathic CD4+ T-lymphocytopenia: a comparison of AIDS and Non-AIDS patients. Intern Med. 2018;57(3):383–386. doi:10.2169/internalmedicine.8746-16
   PubMed Web of Science ®Google Scholar
• He L, Mei X, Lu S, et al. Talaromyces marneffei infection in non-HIV-infected patients in mainland China. Mycoses. 2021;64(10):1170–1176. doi:10.1111/myc.13295
   PubMed Web of Science ®Google Scholar
• Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int. 2009;29(5):491–496. doi:10.1007/s00296-008-0721-6
   PubMed Web of Science ®Google Scholar
• Li Y, Ghannoum M, Deng C, et al. Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping. Int J Infect Dis. 2017;57:108–115. doi:10.1016/j.ijid.2017.02.010
   PubMed Web of Science ®Google Scholar
• Braga BP, Prieto-Gonzalez S, Hernandez-Rodriguez J. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. Med Clin (Barc). 2019;152(12):502–507. doi:10.1016/j.medcli.2019.01.010
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Vital EM, McElvenny DM, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019;71(11):1812–1823. doi:10.1002/art.40937
   PubMed Web of Science ®Google Scholar